1253 related articles for article (PubMed ID: 20932651)
21. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Harris G; Jayamanne D; Wheeler H; Gzell C; Kastelan M; Schembri G; Brazier D; Cook R; Parkinson J; Khasraw M; Louw S; Back M
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):802-810. PubMed ID: 28602411
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
23. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
24. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
25. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
26. Treatment of high-grade gliomas using escalating doses of hypofractionated simultaneous integrated boost-intensity-modulated radiation therapy in combination with temozolomide: A modified Phase I clinical trial.
Ge X; Xue X; Liu H; Wang Y; Xiao Z; Tian L; Chang X; Lin Q; Yu J
J Cancer Res Ther; 2018; 14(7):1482-1491. PubMed ID: 30589027
[TBL] [Abstract][Full Text] [Related]
27. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
28. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Shields LB; Kadner R; Vitaz TW; Spalding AC
Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
[TBL] [Abstract][Full Text] [Related]
29. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma.
Yoon SM; Kim JH; Kim SJ; Khang SK; Shin SS; Cho YH; Jwa E; Park JH; Ahn SD
Tumori; 2013; 99(4):480-7. PubMed ID: 24326836
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
[TBL] [Abstract][Full Text] [Related]
31. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
[TBL] [Abstract][Full Text] [Related]
32. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
[TBL] [Abstract][Full Text] [Related]
33. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme.
Monjazeb AM; Ayala D; Jensen C; Case LD; Bourland JD; Ellis TL; McMullen KP; Chan MD; Tatter SB; Lesser GJ; Shaw EG
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):743-8. PubMed ID: 21236604
[TBL] [Abstract][Full Text] [Related]
34. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
[TBL] [Abstract][Full Text] [Related]
35. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Jalali R; Raut N; Arora B; Gupta T; Dutta D; Munshi A; Sarin R; Kurkure P
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):113-8. PubMed ID: 19647954
[TBL] [Abstract][Full Text] [Related]
36. Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.
Wang TJC; Wu CC; Jani A; Estrada J; Ung T; Chow DS; Soun JE; Saad S; Qureshi YH; Gartrell R; Saadatmand HJ; Saraf A; Garrett MD; Grubb C; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; McKhann GM
Pract Radiat Oncol; 2016; 6(5):306-314. PubMed ID: 26952813
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
[TBL] [Abstract][Full Text] [Related]
38. Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Massaccesi M; Ferro M; Cilla S; Balducci M; Deodato F; Macchia G; Valentini V; Morganti AG
Int J Clin Oncol; 2013 Oct; 18(5):784-91. PubMed ID: 22892797
[TBL] [Abstract][Full Text] [Related]
39. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
40. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Laprie A; Ken S; Filleron T; Lubrano V; Vieillevigne L; Tensaouti F; Catalaa I; Boetto S; Khalifa J; Attal J; Peyraga G; Gomez-Roca C; Uro-Coste E; Noel G; Truc G; Sunyach MP; Magné N; Charissoux M; Supiot S; Bernier V; Mounier M; Poublanc M; Fabre A; Delord JP; Cohen-Jonathan Moyal E
BMC Cancer; 2019 Feb; 19(1):167. PubMed ID: 30791889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]